Electro-needle tongue three needles based on swallowing biomechanics and excitability of the swallowing cortex Mechanism of intervention in swallowing disorders after stroke

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065796

Enrollment

Unknown

Registered

2022-11-15

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Part I tongue needle group:electro-needle tongue three-shot treatment

Part I false stimulation group:false stimulation treatment

Part II tongue needle group:electro-needle tongue three-shot treatment combined with conventional rehabilitation therapy

Part II control group:conventional rehabilitation therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged range from 18 to 80 years, no gender limit; 2. According to the Diagnostic Key Points of Various Major Cerebrovascular Diseases in China 2019 formulated by the Cerebrovascular Department of the Neurology Branch of the Chinese Medical Association, stroke was diagnosed and confirmed by CT or MRI, the course of disease was less than 1 year; 3. The diagnosis of dysphagia is evaluated by a physician and speech therapist, for example, swallowing disorders confirmed by Volume-Viscosity Swallow Test (V-VST); 4. No cognitive dysfunction, no structural lesions of head and neck, no metal implants in neck; 5. Can follow instructions for inspection; Voluntary informed consent.

Exclusion criteria

Exclusion criteria: 1. History of acupuncture adverse reactions; 2. Patients with tracheotomy, patients with continuous oxygen saturation below 95%, patients with artificial ventilator assisted ventilation and patients with unstable vital signs; 3. Structural oral, pharyngeal or esophageal diseases; 4. Serious underlying diseases and complications; 5. Encephalitis, multiple sclerosis, amyotrophic lateral sclerosis, motor neurone disease, poliomyelitis, Guillain-Barre syndrome, myasthenia gravis or myopathy, and Alzheimer's disease; 6. Pregnant and lactating patients.

Design outcomes

Primary

Measure	Time frame
penetration-aspiration scale, PAS;motor evoked potential of mandibular hyoid muscle;	—

Secondary

Measure	Time frame
functionaloral oral intake scale, FOIS;	—

Countries

China

Contacts

Public ContactSun Fang

Yangjiang People's Hospital of Guangdong Province

sunfangdr@163.com+86 13411315069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026